Formulation And Evaluation of Miconazole Pharmacosome by Using Solvent Evaporation Method to Enhance Solubility of Miconazole

This study aims to improve the solubility, bioavailability, and safety profile of miconazole through the development of a pharmacokinetic, a type of vesicular drug delivery system known for its advantages over with conventional methods. Using a solvent evaporation technique, miconazole is encapsulated in a soy lecithin-based pharmacokinetics. The pharmacokinetics obtained showed significant improvements in drug solubility, concentration uniformity and stability. One specific formulation, rated F1, with an exact ratio of miconazole to soy lecithin showed an impressive drug release rate of 94.25% within 60 minutes, in stark contrast to the release rate of only 28.90% achieved by free miconazole. This improved release profile shows the potential to improve treatment efficacy. In addition, both the standard F1 and miconazole formulations exhibited significant antifungal activity against Candida albicans, as evidenced by the minimum inhibitory concentrations (MICs) of 144.23 ?g/ml and 143.31 ?g/ml respectively. The innovative approach of complexing miconazole with soy lecithin through the formation of pharmacokinetics not only enhances drug solubility and bioavailability, but also contributes to minimizing potential toxic effects. These results highlight a promising pharmaceutical role as a means of improving the pharmacological properties of miconazole and other potential drugs with similar solubility challenges. This study has important implications for the development of more effective and safer therapeutic interventions in the field of antifungal therapy